| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.15▼ | 2.15▼ | 2.15▼ | 2.21▼ | 2.22▼ |
| MA10 | 2.15▼ | 2.15▼ | 2.15▼ | 2.23▼ | 2.17▼ |
| MA20 | 2.15▼ | 2.16▼ | 2.19▼ | 2.24▼ | 2.58▼ |
| MA50 | 2.15▼ | 2.22▼ | 2.21▼ | 2.18▼ | 3.16▼ |
| MA100 | 2.17▼ | 2.21▼ | 2.24▼ | 2.60▼ | 3.01▼ |
| MA200 | 2.21▼ | 2.24▼ | 2.25▼ | 3.03▼ | 2.41▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | 0.001▲ | -0.006▼ | -0.014▼ | 0.004▲ |
| RSI | 37.139▼ | 33.050▼ | 35.503▼ | 43.018▼ | 40.249▼ |
| STOCH | 54.167 | 43.304 | 45.785 | 48.486 | 50.842 |
| WILL %R | -100.000▼ | -68.750 | -82.759▼ | -78.125▼ | -65.152 |
| CCI | -271.942▼ | -170.115▼ | -92.960 | -194.737▼ | -21.216 |
|
Thursday, November 06, 2025 01:11 PM
Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line ...
|
|
Tuesday, November 04, 2025 11:01 AM
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today ...
|
|
Wednesday, October 22, 2025 05:46 AM
Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/11/25 | 2.14 | 2.19 | 2.09 | 2.13 | 814,400 |
| 13/11/25 | 2.24 | 2.25 | 2.14 | 2.15 | 916,237 |
| 12/11/25 | 2.30 | 2.31 | 2.22 | 2.24 | 327,955 |
| 11/11/25 | 2.21 | 2.31 | 2.21 | 2.29 | 345,574 |
| 10/11/25 | 2.21 | 2.28 | 2.17 | 2.23 | 646,300 |
| 07/11/25 | 2.19 | 2.33 | 2.06 | 2.19 | 1,400,731 |
| 06/11/25 | 2.24 | 2.29 | 2.19 | 2.25 | 612,700 |
| 05/11/25 | 2.21 | 2.27 | 2.19 | 2.24 | 649,259 |
| 04/11/25 | 2.28 | 2.28 | 2.20 | 2.22 | 619,671 |
| 03/11/25 | 2.35 | 2.35 | 2.25 | 2.31 | 579,600 |
|
|
||||
|
|
||||
|
|